WASHINGTON – The Food and Drug Administration will ask outside experts next week whether the diabetes drug Avandia should be pulled from the market over concerns of heart attack risk.
The FDA scheduled a Monday meeting to ask drug safety and diabetes experts to review GlaxoSmithKline's blockbuster drug after a medical journal article in May suggested it elevates heart attack risk by 43 percent in patients who take the drug.
The agency posted documents Thursday on its Web site that include its latest review of the drug.
FDA is also expected to ask panelists whether any heart attack risks seen with Avandia are greater than those of rival diabetes treatments, which include Takeda Pharmaceutical's Actos, Merck & Co.'s Januvia.
The agency is not required to follow the recommendation of the panel of experts although it usually does. The company says its studies show that the drug is as safe as comparable treatments.
If the panel votes to keep Avandia on the market, as most analysts expect, FDA will ask the group whether a so-called "black box" warning about heart attack risks, or other restrictions should be added to the drug's label.
The FDA said panelists should weigh Avandia's potential risks against its benefits.
More than 6 million people worldwide have taken Avandia or a related drug, Avandamet, since it came on the market in 1999. Doctors use the pills to control blood sugar levels in patients with adult-onset diabetes.
In briefing documents posted online Thursday, Glaxo argued that "there is no consistent or systematic evidence" linking Avandia to increased risk of heart attack or death. However, the company recommends expanding the drug's label, which already includes a warning about heart failure, a condition in which the heart cannot effectively pump blood to the body.
Glaxo said it plans to add a warning that diabetics who already take insulin should not take Avandia. The proposed warning is consistent with the FDA's review, which found insulin-taking patients who also use Avandia face a greater risk of heart failure. Reviewers did not see the same risk in studies of Takeda's Actos, a drug closely-related to Avandia.
Federal lawmakers and consumer groups are pressuring regulators to put further restrictions on Avandia's use. But the agency said it wants to hear from outside experts before recommending any changes.
The British drug maker reported Wednesday that U.S. sales of Avandia fell 31 percent to $226 million in the quarter since safety concerns emerged. Glaxo reported total U.S. sales of $2.2 billion for the drug last year.
Shares of GlaxoSmithKline rose 34 cents to $51.57 in after-hours trading and ended the regular trading session down $1.40 to close at $51.23.